Clinical trial NCT00004880: Vaccine Therapy in Treating Patients With Advanced Kidney Cancer
Official title: A Phase I Pilot Trial of a Multi-Antigen Loaded Dendritic Cell Vaccine for the Treatment of Advanced Renal Cell Carcinoma
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Kidney Cancer
Keywords: stage IV renal cell cancer
recurrent renal cell cancer
Lead sponsor: Jonsson Comprehensive Cancer Center
Sponsor class: OTHER
First posted: 2004-05-20
Enrollment: 14
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Primary purpose: TREATMENT

Brief summary: RATIONALE: Vaccines may make the body build an immune response to kill tumor cells.

PURPOSE: Phase I trial to study the effectiveness of vaccine therapy in treating patients who have advanced kidney cancer.

Detailed description: OBJECTIVES: I. Evaluate the safety of multiantigen loaded dendritic cells (DC) vaccine in patients with advanced renal cell carcinoma. II. Evaluate the immunologic response to this regimen in this patient population. III. Evaluate the clinical response to this regimen in this patient population.

OUTLINE: This is a sequential cohort study. All patients undergo total nephrectomy to harvest primary tumor for vaccine preparation. Patients without primary tumor undergo surgical resection of the accessible metastatic site for vaccine preparation. Patients are assigned to 1 of 4 treatment arms. Arm I: Patients receive vaccination with irradiated autologous tumor lysate (TuLy) intradermally (ID) on day 0 followed by vaccination with multiantigen liposome loaded dendritic cells (DC) ID on days 7, 14, and 21. Arm II: Patients receive vaccinations as in arm I, except DC are pulsed with tumor cells. Arm III: Patients receive vaccination with irradiated autologous tumor lysate (TuLy) IV on day 0 followed by vaccination with multiantigen liposome loaded DC IV on days 7, 14, and 21. Arm IV: Patients receive vaccinations as in arm III, except DC are treated as in arm II. Patients are followed on days 28, 42, 70, and 112.

PROJECTED ACCRUAL: A total of 24 patients will be accrued for this study.

Eligibility criteria: Inclusion Criteria:

* Histologically confirmed metastatic renal cell carcinoma Evaluable or bidimensionally measurable disease with primary renal tumor in place or surgically accessible metastatic site greater than 2 x 2 cm
* Over 18
* ECOG 0-1
* Hematopoietic:

  * Hemoglobin at least 10 g/dL (not transfusion dependent)
  * Platelet count at least 75,000/mm3
  * WBC greater than 3,000/mm3
* Hepatic: SGOT/SGPT no greater than 5 times upper limit of normal (ULN)
* Alkaline phosphatase no greater than 5 times ULN
* PT/PTT no greater than 1.5 times ULN
* Bilirubin no greater than 2.5 mg/dL
* Renal: Creatinine no greater than 2.0 g/dL
* Hepatitis B surface antigen negative
* Negative pregnancy test
* Fertile patients must use effective contraception
* At least 4 weeks since prior immunotherapy
* At least 4 weeks since prior chemotherapy
* At least 4 weeks since prior radiotherapy
* At least 14 days since prior acute therapy for infection

Exclusion Criteria:

* uncontrolled CNS metastasis
* ischemic heart disease that precludes surgery
* pulmonary condition that precludes surgery
* other underlying condition or allergy that would preclude study
* acute viral, bacterial, or fungal infection requiring therapy HIV negative
* pregnant or nursing
* other acute medical problems that would preclude study
* concurrent corticosteroids (oral, topical, inhaled)
* prior organ allografts

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Los Angeles
country: United States
facility: Jonsson Comprehensive Cancer Center, UCLA
state: California
Study officials:
affiliation: Jonsson Comprehensive Cancer Center
name: Barbara J. Gitlitz, MD
role: STUDY_CHAIR
References: